Disease-Modifying Antirheumatic Drugs

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:drug
gptkbp:abbreviation	gptkb:DMARDs
gptkbp:alternativeTo	gptkb:NSAIDs corticosteroids
gptkbp:approvedBy	gptkb:FDA gptkb:EMA
gptkbp:category	immunosuppressive agents anti-inflammatory agents
gptkbp:compatibleWith	acute symptom relief
gptkbp:contraindication	pregnancy (for some DMARDs)
gptkbp:discoveredIn	20th century
gptkbp:firstLineTreatmentFor	rheumatoid arthritis
gptkbp:goal	improve quality of life prevent joint damage maintain function
https://www.w3.org/2000/01/rdf-schema#label	Disease-Modifying Antirheumatic Drugs
gptkbp:includes	gptkb:cyclosporine gptkb:methotrexate gptkb:leflunomide gptkb:biologic_DMARDs gptkb:sulfasalazine gptkb:targeted_synthetic_DMARDs azathioprine hydroxychloroquine
gptkbp:mechanismOfAction	modulate immune system reduce inflammation slow disease progression
gptkbp:monitors	regular blood tests
gptkbp:onset	weeks to months
gptkbp:prescribes	rheumatologist
gptkbp:regulates	immune response
gptkbp:routeOfAdministration	oral subcutaneous intravenous
gptkbp:sideEffect	immunosuppression liver toxicity gastrointestinal upset bone marrow suppression
gptkbp:subclassOf	gptkb:biologic_DMARDs gptkb:conventional_synthetic_DMARDs gptkb:targeted_synthetic_DMARDs
gptkbp:usedFor	gptkb:juvenile_idiopathic_arthritis gptkb:systemic_lupus_erythematosus gptkb:psoriatic_arthritis rheumatoid arthritis ankylosing spondylitis
gptkbp:bfsParent	gptkb:DMARDs
gptkbp:bfsLayer	7